Stony Brook Medicine conducts clinical trials of Novavax's COVID-19 vaccine

STONY BROOK, N.Y. (WCBS 880) — The Pfizer and Moderna vaccines are on the market and others are still in the pipeline.

WCBS 880's Peter Haskell checked in with Stony Brook Medicine on Long Island, which is conducting clinical trials for the two-dose Novavax vaccine.

There are 30,000 people involved in the Phase 3 trial. More than 100 have received shots at Stony Brook and they're looking for more.

"It continues to enroll very briskly," said Dr. Benjamin Luft, the chief investigator.

He said this is a protein-based vaccine.

"This is basically made from a recombinant protein that is the same as what you find in the virus itself," he said.

As more vaccines come online, there is hope ground will be gained on the pandemic.

"There will be a real impact on the mortality rate," Luft said, adding that early results show the Novavax product is safe and effective. "It has a very good safety profile and it has very good Immunogenicity."

LISTEN NOW on the RADIO.COM App
Follow WCBS Newsradio 880
Facebook | Twitter | Instagram